Cargando…
Fatal Acute Hemorrhagic Encephalomyelitis and Antiphospholipid Antibodies following SARS-CoV-2 Vaccination: A Case Report
Acute hemorrhagic encephalomyelitis (AHEM) is a rare hyperacute form of acute disseminated encephalomyelitis (ADEM). The disease is characterized by fulminant inflammation and demyelination in the brain and spinal cord and is often preceded by an infection or vaccination. This case report presents a...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9784396/ https://www.ncbi.nlm.nih.gov/pubmed/36560456 http://dx.doi.org/10.3390/vaccines10122046 |
_version_ | 1784857801667903488 |
---|---|
author | Kits, Annika Pantalone, Mattia Russel Illies, Christopher Antovic, Aleksandra Landtblom, Anne-Marie Iacobaeus, Ellen |
author_facet | Kits, Annika Pantalone, Mattia Russel Illies, Christopher Antovic, Aleksandra Landtblom, Anne-Marie Iacobaeus, Ellen |
author_sort | Kits, Annika |
collection | PubMed |
description | Acute hemorrhagic encephalomyelitis (AHEM) is a rare hyperacute form of acute disseminated encephalomyelitis (ADEM). The disease is characterized by fulminant inflammation and demyelination in the brain and spinal cord and is often preceded by an infection or vaccination. This case report presents a 53-year-old male with rheumatoid arthritis and ongoing treatment with methotrexate and etanercept who developed fatal AHEM following the second dose of the COVID-19 vaccine. The disease course was complicated by multiorgan thromboembolic disease and the presence of high/moderate levels of cardiolipin IgG antibodies and anti-beta-2 glycoprotein 1 IgG antibodies suggesting a possible antiphospholipid syndrome. Treatment with immunosuppressive therapies failed to improve the course. The report comprises comprehensive clinical, neuroimaging, and neuropathological findings. The case highlights diagnostic challenges in a patient with several preceding risk factors, including autoimmune disease, immunotherapy, and vaccination, with possible pathophysiological implications. The temporal association with the COVID-19 vaccination may suggest possible causality although evidence cannot be ascertained. Reporting possible adverse events following COVID-19 vaccination is important to identify at-risk populations and to accomplish control of the current pandemic. |
format | Online Article Text |
id | pubmed-9784396 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-97843962022-12-24 Fatal Acute Hemorrhagic Encephalomyelitis and Antiphospholipid Antibodies following SARS-CoV-2 Vaccination: A Case Report Kits, Annika Pantalone, Mattia Russel Illies, Christopher Antovic, Aleksandra Landtblom, Anne-Marie Iacobaeus, Ellen Vaccines (Basel) Case Report Acute hemorrhagic encephalomyelitis (AHEM) is a rare hyperacute form of acute disseminated encephalomyelitis (ADEM). The disease is characterized by fulminant inflammation and demyelination in the brain and spinal cord and is often preceded by an infection or vaccination. This case report presents a 53-year-old male with rheumatoid arthritis and ongoing treatment with methotrexate and etanercept who developed fatal AHEM following the second dose of the COVID-19 vaccine. The disease course was complicated by multiorgan thromboembolic disease and the presence of high/moderate levels of cardiolipin IgG antibodies and anti-beta-2 glycoprotein 1 IgG antibodies suggesting a possible antiphospholipid syndrome. Treatment with immunosuppressive therapies failed to improve the course. The report comprises comprehensive clinical, neuroimaging, and neuropathological findings. The case highlights diagnostic challenges in a patient with several preceding risk factors, including autoimmune disease, immunotherapy, and vaccination, with possible pathophysiological implications. The temporal association with the COVID-19 vaccination may suggest possible causality although evidence cannot be ascertained. Reporting possible adverse events following COVID-19 vaccination is important to identify at-risk populations and to accomplish control of the current pandemic. MDPI 2022-11-30 /pmc/articles/PMC9784396/ /pubmed/36560456 http://dx.doi.org/10.3390/vaccines10122046 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Case Report Kits, Annika Pantalone, Mattia Russel Illies, Christopher Antovic, Aleksandra Landtblom, Anne-Marie Iacobaeus, Ellen Fatal Acute Hemorrhagic Encephalomyelitis and Antiphospholipid Antibodies following SARS-CoV-2 Vaccination: A Case Report |
title | Fatal Acute Hemorrhagic Encephalomyelitis and Antiphospholipid Antibodies following SARS-CoV-2 Vaccination: A Case Report |
title_full | Fatal Acute Hemorrhagic Encephalomyelitis and Antiphospholipid Antibodies following SARS-CoV-2 Vaccination: A Case Report |
title_fullStr | Fatal Acute Hemorrhagic Encephalomyelitis and Antiphospholipid Antibodies following SARS-CoV-2 Vaccination: A Case Report |
title_full_unstemmed | Fatal Acute Hemorrhagic Encephalomyelitis and Antiphospholipid Antibodies following SARS-CoV-2 Vaccination: A Case Report |
title_short | Fatal Acute Hemorrhagic Encephalomyelitis and Antiphospholipid Antibodies following SARS-CoV-2 Vaccination: A Case Report |
title_sort | fatal acute hemorrhagic encephalomyelitis and antiphospholipid antibodies following sars-cov-2 vaccination: a case report |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9784396/ https://www.ncbi.nlm.nih.gov/pubmed/36560456 http://dx.doi.org/10.3390/vaccines10122046 |
work_keys_str_mv | AT kitsannika fatalacutehemorrhagicencephalomyelitisandantiphospholipidantibodiesfollowingsarscov2vaccinationacasereport AT pantalonemattiarussel fatalacutehemorrhagicencephalomyelitisandantiphospholipidantibodiesfollowingsarscov2vaccinationacasereport AT illieschristopher fatalacutehemorrhagicencephalomyelitisandantiphospholipidantibodiesfollowingsarscov2vaccinationacasereport AT antovicaleksandra fatalacutehemorrhagicencephalomyelitisandantiphospholipidantibodiesfollowingsarscov2vaccinationacasereport AT landtblomannemarie fatalacutehemorrhagicencephalomyelitisandantiphospholipidantibodiesfollowingsarscov2vaccinationacasereport AT iacobaeusellen fatalacutehemorrhagicencephalomyelitisandantiphospholipidantibodiesfollowingsarscov2vaccinationacasereport |